Cochrane review finds little evidence in support of common neuropathic pain drug

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Rigorous analysis suggests that oxcarbazepine (eg, Trileptal) shows limited efficacy in the treatment of several different forms of neuropathic pain.

Why this matters

  • Studies suggest that oxcarbazepine was safer, better tolerated, and had a lower risk for drug-drug int...